|
Category:enzyme preparations and microorganisms
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Food Chemicals Codex Listed: | No |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
oral-rat LD50 7500 ul/kg
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 13, Pg. 919, 1971.
intravenous-rat LD50 7568 mg/kg
Yamaguchi Igaku. Yamaguchi Medicine. Vol. 18, Pg. 271, 1969.
intraperitoneal-rat LD50 8204 mg/kg
Yamaguchi Igaku. Yamaguchi Medicine. Vol. 18, Pg. 271, 1969.
intravenous-rabbit LD50 2.273 mg/kg
Yamaguchi Igaku. Yamaguchi Medicine. Vol. 18, Pg. 271, 1969.
|
| Dermal Toxicity: |
subcutaneous-rat LD50 8204 mg/kg
Yamaguchi Igaku. Yamaguchi Medicine. Vol. 18, Pg. 271, 1969.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | enzyme preparations and microorganisms |
| Recommendation for asparaginase from aspergillus oryzae expressed in aspergillus oryzae usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for asparaginase from aspergillus oryzae expressed in aspergillus oryzae flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | asparaginase from aspergillus oryzae expressed in aspergillus oryzae |
Articles:
|
nci: an enzyme isolated from the bacterium escherichia coli or the bacterium erwinia carotovora with antileukemic activity. asparaginase hydrolyzes l-asparagine to l-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the g1 phase, and apoptosis in susceptible leukemic cell populations. see more at nci
|